FDA Approves EPINEPHRINE — Baxter Healthcare Corporation

# FDA Approves Baxter Healthcare's Intramuscular Epinephrine Formulation Baxter Healthcare Corporation received FDA approval for its intramuscular epinephrine formulation (NDA220626) on March 30, 2026, potentially strengthening the company's position in the critical emergency pharmaceutical market and expanding treatment options for anaphylaxis management. The approval could capture additional market share in the competitive epinephrine auto-injector and emergency injection space, where demand remains robust due to rising food allergy prevalence and widespread adoption of epinephrine as a first-